(Q39515308)

English

Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).

scientific article published on 4 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Paul Whi Parren

9

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

author name string

Katja Klausz

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sven Berger

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Jeroen J Lammerts van Bueren

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Stefanie Derer

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Stefan Lohse

5

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Michael Dechant

6

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Jan G J van de Winkel

7

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Matthias Peipp

8

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Thomas Valerius

10

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

publication date

4 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

102

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1761-1768

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Structure and clinical relevance of the epidermal growth factor receptor in human cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Effector mechanisms of therapeutic antibodies against ErbB receptors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Mutant epidermal growth factor receptors as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Serum-free production and purification of chimeric IgA antibodies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Engineered antibodies with increased activity to recruit complement

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

RETRACTED: The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Cancer. Addiction to oncogenes--the Achilles heal of cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Complement: a key system for immune surveillance and homeostasis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02019.X

21 January 2018

Identifiers

10.1111/J.1349-7006.2011.02019.X

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39515308&oldid=1460399770"